ResultsIQ

ResultsIQ › Latest results › Novartis India Limited

Novartis India Limited Q2 FY27 results press release summary

NSE: NOVARTIND · BSE: 500672

Results press release of 3 Nov 2026, summarised by AI from the filing.

Evonile Pharma's first results after ChrysCapital's 70.68% controlling stake: Q2 FY27 revenue ₹56.1 cr and operating EBITDA -₹31.8 cr.

Key takeaways

  1. Q2 revenue Revenue from operations was ₹56.1 cr in Q2 FY27.
  2. Operating EBITDA Operating EBITDA was -₹31.8 cr, reflecting one-time transition costs and upfront investment in the organisational build-out.
  3. Change of control ChrysCapital acquired a controlling 70.68% stake in the Company during the quarter.
  4. New model The Company moved from a single-customer business model to its own distribution network, field force and operating systems.
  5. Portfolio The Company completed the Minipress XL acquisition and an ophthalmology in-licensing agreement, adding cardiology and ophthalmology.

Original filing on BSE

Novartis India Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.